Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2012 Financial Results
Nov 7, 2012
PDF 108.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Participate in the Brean Capital 2012 Life Sciences Summit
Nov 6, 2012
PDF 107.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third-Generation Anti-CD20 Monoclonal Antibody, Ublituximab, in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Sep 5, 2012
PDF 113.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Poster Presentation for Ublituximab (TGTX-1101) at the 7th International Workshop on Waldenstrom's Macroglobulinemia
Aug 24, 2012
PDF 126.9 KB Add to Briefcase
View Summary TG Therapeutics and Rhizen Pharmaceuticals Announce Global Agreement for Development and Commercialization of Novel PI3K Delta Selective Inhibitor, TGR-1202
Aug 16, 2012
PDF 49.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Investigational New Drug (IND) for TGTX-1101, Receives Clearance by the FDA to Commence Clinical Trials in the U.S.
May 14, 2012
PDF 12.8 KB Add to Briefcase
View Summary Manhattan Pharmaceuticals, Inc. Announces Name Change to TG Therapeutics, Inc. and Reverse Stock Split
Apr 27, 2012
PDF 44.5 KB Add to Briefcase
View Summary TG Therapeutics Completes Licensing Agreement With LFB Biotechnologies for the Development of Ublituximab
Mar 2, 2012
PDF 32.1 KB Add to Briefcase
Showing 221-228 of 228 Page: 1 ... 8 9 10 11 12  Previous 20
Add to Briefcase = add release to Briefcase